CTNM Contineum Therapeutics, Inc.
Research report · from SEC EDGAR · close 2026-07-13
$14.62 -3.8%
$337.7M mkt cap
executive summary
Contineum Therapeutics, Inc. (CTNM) is a $337.7M company. Revenue is $0 (-100.0% y/y). It is not yet profitable. Our health score is C (66/100). 3 red flags on file. It funds itself; low dilution risk.
Revenue (FY)
$0
-100.0% y/y
⚠Active dilution shelf
An effective S-3 shelf with 3 prospectus filing(s) in 12 months — shares may be getting sold into the market.
⚠Weak fundamentals
Piotroski F-Score of 1/9 — most quality checks are failing.
⚠One-sided insider selling
16 insider sales and no open-market buys in the recent window.
who's buying
Insider buys / sells
0 / 16
Cash & ST investments
$246.3M
Operating cash flow
-$55.3M
Dilution shelf
active shelf
FILINGReg FD disclosure
8-K filed 2026-07-13
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices — every figure is real and sourced; nothing is fabricated or predicted. Filings lag 40–90 days. Educational, not investment advice. Generated 2026-07-13 by stocktools.ai.